Capecitabine

About

Therapy type: Chemotherapy

Therapy strategy: Thymidylate synthase inhibition

Mappings

NCI Thesaurus: Capecitabine (coding:ncit:C1794)

RxNorm: capecitabine (coding:rxcui:194000, coding:omop:1337620)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
EMA (1) FDA (2) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
FDA (2) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (2) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (2) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
EMA (1) FDA (2) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
EMA (1) FDA (2) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
EMA (1) HER2-positive Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Capecitabine, Lapatinib
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Stomach Adenocarcinoma Capecitabine, Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Nivolumab, Oxaliplatin
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Capecitabine, Nivolumab, Oxaliplatin